SVR on DAA-only regimens provided a 71% reduction in de novo HCC risk.
At 3 years of follow-up, 37% of participants self-reported injection drug use, with an overall reinfection rate of 2.3 per 100 person-years.
Treatment generally well tolerated with no loss of HIV-1 RNA suppression.
HCC incidence similar with DAAs vs IFN in cirrhotic patients and regardless of whether patients achieved SVR.
No benefit noted with extension of treatment from 8 weeks to 12 weeks among noncirrhotic patients.
Clinical cohort study observed no additional benefit with use of ribavirin in cirrhotic patients, nor any negative impact of baseline RASs.
In this single-center study from Johns Hopkins, one third of HCV/HIV-coinfected patients did not start HCV treatment despite adherence, nursing and pharmacy support models.
Large observational cohort provides clear evidence of clinical benefits of curative DAA therapy.
1-year mortality risk in patients with decompensated cirrhosis 61% lower with DAA therapy vs pre-DAA era treatment.
Reduction in mortality appeared greater for liver-related vs nonliver-related events.
SVR12 rate of 98% with no grade 3/4 adverse events at interim analysis.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.